Fendx Technologies files patent application in U.S.

Executive Summary

• Fendx Technologies Inc. filed a provisional patent application (No. 63/936,328) for a novel antimicrobial nanoparticle liquid coating designed for long-lasting pathogen control on high-touch surfaces.
• The technology, formerly described as a spray, is engineered for easy application via roller or brush and actively disrupts microbial contamination.
• The company is currently assessing scale-up and distribution partnership opportunities to commercialize the technology.

Key Details

• Patent Filing Details:
  • Application Number: 63/936,328
  • Title: "Antimicrobial Coating for Long-Lasting Pathogen Control on High-Touch Surfaces"
  • Filing Date: August 7, 2025
  • Assignee: Fendx Technologies Inc.
  • Inventors: Dr. Carolyn Myers, Dr. Tohid Didar, Dr. Leyla Soleymani, and Dr. Sara Moetakef Imani.
• Technology Specifications:
  • Type: Novel nanoparticle liquid coating.
  • Function: Provides long-lasting protection against a broad spectrum of pathogens on high-touch surfaces.
  • Mechanism: Leverages nanoparticle technology to actively disrupt microbial contamination.
  • Application Method: Designed for easy application using standard tools such as a roller or brush.
• Strategic Updates:
  • The company is actively assessing scale-up and distribution partnership opportunities.
  • The filing adds to Fendx's expanding portfolio of hygiene-related technologies.
• Company Pipeline Context:
  • Fendx is advancing other products including "Repelwrap" film (protective surface coating) and specialized catheter coatings (specifically for Foley catheters).
  • The company holds exclusive worldwide licenses and intellectual property for its coating technologies.

Notable Quotes

• "We are pleased with the progress of our development efforts on this liquid coating technology, which have resulted in the filing of this patent application," said Dr. Myers, chief executive officer of Fendx. "We are now actively assessing scale-up and distribution partnership opportunities to bring this technology to the market. This innovation underscores Fendx's commitment to developing scalable solutions aimed at reducing infection risk."